Clusterin is epigenetically regulated in prostate cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Lack of good models has complicated investigations on the mechanisms of prostate cancer. By far, the most commonly used transgenic mouse model of prostate cancer is TRAMP, which, however, has not been fully characterized for genetic and epigenetic aberrations. Here, we screened TRAMP‐derived C2 cell line for the alterations using different microarray approaches, and compared it to human prostate cancer. TRAMP‐C2 had relatively few genomic copy number alterations according to array comparative genomic hybridization (aCGH). However, the gene copy number and expression were significantly correlated (p < 0.001). Screening genes for promoter hypermethylation using demethylation treatment with 5‐aza‐2′‐deoxycytidine and subsequent expression profiling indicated 43 putatively epigenetically silenced genes. Further studies revealed that clusterin is methylated in the TRAMP‐C2 cell line, as well as in the human prostate cancer cell line LNCaP. Its expression was found to be significantly reduced (p < 0.01) in untreated and hormone‐refractory human prostate carcinomas. Together with known function of clusterin, the data suggest an epigenetic component in the regulation of clusterin in prostate cancer. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jones, S. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00155-8 · Cited by 488
Clusterin inhibits apoptosis by interacting with activated Bax
Zhang, H., Kim, J. K., Edwards, C. A., Xu, Z., Taichman, R., & Wang, C.-Y. (2005) · Nature Cell Biology · doi:10.1038/ncb1291 · Cited by 453
Cited by
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
“The CLU gene is more clearly regulated by epigenetic mechanisms, as its promoter regions contain a CpG island, the demethylation of which after 5-aza-2’-deoxycytidine (decitabine; DAC) treatment was shown to enhance CLU expression in cancer cell lines (Rauhala et al., 2008).”
BackgroundClusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
Clusterin: A forgotten player in Alzheimer's disease
Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.007 · Cited by 267
Gasparoni, G., Bultmann, S., Lutsik, P., Kraus, T. F. J., Sordon, S., Vlcek, J., Dietinger, V., Steinmaurer, M., Haider, M., Mulholland, C. B., et al. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0211-3 · Cited by 229
The Role of Clusterin in Alzheimer’s Disease: Pathways, Pathogenesis, and Therapy
Yu, J.-T., & Tan, L. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8237-1 · Cited by 174
“The demethylation with 5-aza-2′-deoxycytidine in prostate cancer cell lines significantly increases the expression of CLU [31], and the treatment with histone deacetylase”
Metadata
- Authors
- Rauhala, H. E., Porkka, K. P., Saramäki, O. R., Tammela, T. L. J., & Visakorpi, T.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2008-07-22
- Volume
- 123
- Issue
- 7
- Pages
- 1601-1609
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2138662623
- Cited by
- 57
- References
- 2
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clusterin is epigenetically regulated in prostate cancer. https://app.cochat.ai/papers/10.1002/ijc.23658
- The paper
- Rauhala, H. E., Porkka, K. P., Saramäki, O. R., Tammela, T. L. J., & Visakorpi, T. (2008). Clusterin is epigenetically regulated in prostate cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.23658
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.